Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode Ltd. (Nasdaq: INMD), a global leader in innovative medical technologies, will present at the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 9:15 am EST. CEO Moshe Mizrahy and CFO Yair Malca will lead the presentation, which will be webcast live and archived for 90 days. Management will also offer one-on-one virtual meetings during the event. InMode specializes in minimally invasive radio-frequency technologies for various medical fields, including plastic surgery and dermatology.
InMode Ltd. (Nasdaq: INMD) announced participation in three virtual investor conferences. CEO Moshe Mizrahy and CFO Yair Malca will present at the Stifel 2021 Healthcare Conference on November 16 at 9:20 PM EST, the Hidden Gem Conference on November 17 at 11:15 AM EST, and the Canaccord Virtual MedTech Forum on November 18 at 1:30 PM EST. Webcasts will be available for the Stifel and Canaccord events. Investors can schedule one-on-one virtual meetings during these conferences.
InMode Ltd. (Nasdaq: INMD) reported record revenues of $94.2 million for Q3 2021, a 58% increase from Q3 2020. The company's GAAP net income reached $44.7 million, resulting in a GAAP diluted EPS of $0.52, up from $0.28 a year prior. Non-GAAP net income was $47.9 million, with an EPS of $0.55. The company has a total cash position of $387.4 million as of September 30, 2021. Looking ahead, InMode projects 2021 revenues between $343 million and $347 million.
InMode Ltd. (NASDAQ: INMD) announced expectations for record revenue for Q3 2021, projecting between $93.5M and $94M. The company also anticipates Non-GAAP earnings per diluted share to be in the range of $0.53 to $0.54, reflecting a 2-for-1 stock split effective September 30, 2021. Full-year revenue guidance has been raised to $343M - $347M with a Non-GAAP gross margin of 84% - 86%. A conference call to discuss results will take place on October 26, 2021.
InMode Ltd. (Nasdaq: INMD) has announced a two-for-one (2:1) share split, effective September 30, 2021, with a record date of September 27, 2021. Every share held by shareholders on the record date will automatically convert into two shares, impacting all shareholders uniformly without affecting their ownership percentage. The share split was approved by the board of directors on September 14, 2021. This move aims to enhance the liquidity of the shares and make them more accessible to investors.
InMode Ltd. (Nasdaq: INMD), a leader in innovative medical technologies, will participate in two upcoming virtual conferences. On September 14, CEO Moshe Mizrahy and CFO Yair Malca will present at the Baird Global Healthcare Conference at 4:20 PM ET. Additionally, they will participate in the Citi Small-Mid Cap Growth Conference on September 17, with opportunities for one-on-one meetings. Access to the conference webcasts can be found here.
InMode Ltd. (Nasdaq: INMD) has launched the EvolveX platform featuring Transform technology, designed for hands-free, non-invasive body transformation with zero downtime. The platform meets rising post-lockdown demand for non-surgical treatments, offering a unique all-in-one solution that remodels skin, treats fat, and sculpts muscles. EvolveX’s innovative features allow physicians to customize treatments addressing specific patient needs, promising consistent results. CEO Moshe Mizrahy emphasized the growing demand for such solutions, backed by InMode's strong R&D pipeline.
InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness platform, designed to deliver advanced feminine wellness therapies. This multi-functional solution utilizes various complementary technologies to address a range of conditions such as pain relief, blood circulation, and urinary incontinence. CEO Moshe Mizrahy emphasized the company's commitment to addressing unmet needs in women's wellness, while North American President Shakil Lakhani highlighted InMode's ongoing investment in this market despite competitors withdrawing. The platform aims to improve women's quality of life through minimally invasive procedures.
InMode Ltd. (Nasdaq: INMD), a leader in medical technologies, announced its participation in key upcoming conferences. On August 12, Yair Malca, CFO, will engage in a virtual fireside chat at Canaccord Genuity's Growth Virtual Conference, while Moshe Mizrahy, CEO, joins him for a similar event at UBS Genomics 2.0 in Laguna Beach. Additionally, both executives will be available for one-on-one meetings at the Needham Virtual Med Tech Conference on August 16. For more details, visit InMode's events page.
InMode Ltd. (Nasdaq: INMD) reported a remarkable 184% increase in second-quarter 2021 revenues, reaching $87.3 million, driven primarily by its proprietary surgical technologies. GAAP net income surged to $40.9 million, up from $8.6 million in Q2 2020, with diluted EPS rising to $0.95. The company boasts a strong cash position of $332.9 million. Management's outlook for 2021 anticipates revenues between $305 million and $315 million, with non-GAAP EPS projected between $3.10 and $3.25. InMode is also launching a new platform, Empower, focused on women's health.